pSivida Corp. Announces Fourth Quarter and Fiscal Year 2013 Financial Results Release Date and Conference Call Information

  pSivida Corp. Announces Fourth Quarter and Fiscal Year 2013 Financial
  Results Release Date and Conference Call Information

Business Wire

WATERTOWN, Mass. -- September 18, 2013

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained
release, drug delivery products for treatment of back-of-the-eye diseases,
today announced that its financial results for the fourth quarter and fiscal
year 2013 will be released after the market close on Wednesday, September 25,
2013, followed the same day by a conference call and live webcast scheduled
for 4:30 p.m. ET.

The conference call may be accessed by dialing (877) 312-7505 from the U.S.
and Canada, or (631) 813-4828 from international locations. A live webcast
will be available on the Investor Relations section of the corporate website
at http://www.psivida.com.

A replay of the call will be available beginning September 25, 2013 at
approximately 7:30 p.m. ET and ending on October 2, 2013. The replay may be
accessed by dialing (855) 859-2056 within the U.S. and Canada or (404)
537-3406 from international locations, Conference ID Number: 68809431. A
replay of the webcast will also be available on the corporate website during
that time.

About pSivida Corp.

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drug delivery products designed to deliver drugs at a controlled and
steady rate for months or years. pSivida is currently focused on treatment of
chronic diseases of the back of the eye utilizing its core technology systems,
Durasert™ and BioSilicon™. The injectable, sustained release micro-insert
ILUVIEN® for the treatment of chronic DME, licensed to Alimera Sciences, Inc.,
has received marketing authorization in Austria, France, Germany, Portugal,
Spain and the U.K. and is awaiting authorization in Italy. ILUVIEN for DME has
not been approved in the U.S. pSivida has begun pivotal Phase III clinical
trials for the treatment of posterior uveitis, a chronic back-of-the-eye
disease, with the same micro-insert as ILUVIEN for DME. An
investigator-sponsored clinical trial is ongoing for an injectable,
bioerodible micro-insert to treat glaucoma and ocular hypertension. pSivida's
FDA-approved Retisert® licensed to Bausch & Lomb Incorporated provides
long-term, sustained drug delivery to posterior uveitis.

Follow pSivida on social media:

Twitter: https://twitter.com/pSividaCorp

Facebook: https://www.facebook.com/pages/PSivida-Corp/544893792199562

LinkedIn: http://www.linkedin.com/company/psivida

Google+:
https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts

The President's Blog: http://www.thechairmansblog.com/paul-ashton

For more information on pSivida, visit www.psivida.com.

Contact:

In US:
Martin E. Janis & Company, Inc.
Beverly Jedynak
President
Tel: +1 (312) 943 1123
bjedynak@janispr.com
or
In Australia:
pSivida Corp.
Brian Leedman
Vice President, Investor Relations
+61 (0) 41 228 1780
brianl@psivida.com